AlphaStreet Newsdesk powered by AlphaStreet Intelligence
GDRX|EPS $0.08 vs $0.08 est (+0.0%)|Rev $200.4M vs $193.2M est (+3.8%)|Internet Revenue $8.5M
GoodRx Holdings, Inc. matched analyst expectations with adjusted earnings of $0.08 per share for the primary half of 2026, assembly the consensus estimate from 12 analysts. The prescription drug value comparability platform posted income of $200.4M, beating the $193.2M consensus by 3.8%, although gross sales slipped 1.3% from $203.1M within the year-ago interval. Backside-line revenue got here in at $26.8M.
The corporate’s core Prescription transactions phase generated $106.4M in income however confronted headwinds, declining 25.7% year-over-year. Pharma Direct income supplied a partial offset at $61.6M for the quarter. The platform maintained a considerable person base with 25,000,000 lively customers at quarter finish, reflecting the continued demand for clear prescription pricing instruments amid rising healthcare prices.
Administration issued full-year steering calling for income between $790.0M and $805.0M, offering path as the corporate navigates a aggressive digital well being panorama. The blended outcomes underscore the challenges GoodRx faces in sustaining development whereas sustaining its established shopper base in an evolving pharmaceutical market.
This content material is for informational functions solely and shouldn’t be thought of funding recommendation. AlphaStreet Intelligence analyzes monetary information utilizing AI to ship quick and correct market info. Human editors confirm content material.
